


Getting Better Faster

Delivering on the Promise of New TB Treatments

Launch Webinar – 27 March 2024

Chaired by David Branigan



1/4/6x24

A Campaign to Rally
Energy, Political Will
& Funding to End TB

Today's agenda


Welcome note

Taking stock at the campaign midpoint

Centering the needs of people affected by TB


Learning from 1/4/6 country leaders

Q&A



Welcome note


Dr. Suvanand Sahu, Deputy Executive Director




Stop TB Partnership

Taking stock at the midpoint of the 1/4/6x24 Campaign

Madlen Nash



A campaign to realize access to the best possible TB treatments for everyone, everywhere



A deadline for having in place the “staff, stuff, space, systems, and support” needed for shorter TB regimens to be made accessible to everyone, everywhere as a human right.

& priority research to extend the benefits of short treatment and prevention regimens to any groups who cannot currently use them due to data gaps or research exclusions.

Where are we now?

July 2022 The 1/4/6x24 Campaign is launched by TAG, PIH, and MSF at AIDS 2022

July 2022 Global Fund includes 1/4/6 regimens as program essentials in its Information Note for TB

October 2022 USAID hosts 1/4/6x24 Campaign Call-to-Action. Key global health actors made commitments to the campaign

November 2022 GFAN publishes advocacy guides to support inclusion of 1/4/6 regimens in national strategic plans and Global Fund funding requests

September 2023 Member states adopt a political declaration at the United Nations High-Level Meeting on TB recognizing the right to science and the need to scale up access to shorter, safer TB regimens

March 2024 Launch of mid-campaign report



9 months!

December 2024

Deadline to meet the goals of the 1/4/6x24 Campaign



3.5 years!

September 2027

Deadline for countries to meet funding and implementation commitments made at the 2023 United Nations High-Level Meeting on TB



The “1”: preventive treatment

1HP – 1 month daily
3HP – 3 months once weekly
3HR – 3 months daily, for kids

Progress

Provision of rifamycin-based TPT is increasing year-on-year

Most countries have plans to implement 3HP*

Shorter regimens are cost-effective

Fixed-dose combinations reduced pill burden

Child-friendly formulations now exist

Priorities

Improve TPT coverage for children using short, child-friendly formulations – only 37% of at-risk children received TPT in 2022

Expand access to TPT – only reached 50% of 2018-2022 UN target

Improve coverage for people ≥ 5 years old not living with HIV

Expand access to 1HP (which is more limited compared to 3HP*)

4HPMZ – 4 months for adults & adolescents

The “4”: Drug-susceptible TB treatment



Progress

Growing demand for 4HPMZ*

Anticipated fixed-dose combinations to reduce pill burden

Priorities

Increase demand & volumes → reduce cost


Implementation science to inform roll out

Update national guidelines

Increase access to drug susceptibility testing

Evaluate in children and pregnant populations

Potential impact of implementing 4HPMZ through 2030



*Data from Global Fund concept note analysis.

4HRZE for kids with nonsevere disease

The “4”: Drug-susceptible TB treatment



Progress

Quality assured, fixed-dose combinations already exist

4HRZE was included as a Global Fund program essential

At least 25 countries have plans to scale up 4HRZE for children*

Priorities

Increase demand

Develop clinical algorithms and monitoring tools to support provision of 4HRZE in absence of chest X-ray

Update national guidelines

Improve pediatric diagnostic algorithms and tests

“My advice to other countries is to champion children. Don’t be afraid to amend guidelines and diagnostic processes. Thanks to the changes we’ve implemented, we are expecting an increase in detection of pediatric TB and an improved treatment success rate.” — Dr Kathure

The “6”: Drug-resistant TB treatment




Progress

- Extensive operational research showing success
- Most countries have plans to scale up BPaL[M]*
- Increased procurement of pretomanid suggesting increased use of regimen
- Decreased regimen cost
- Many, many, many months saved on treatment

Priorities

- Increase implementation of BPaL[M] to meet need – 175,650 people treated in 2022
- Increase access to diagnosis and drug-susceptibility testing – only 43% diagnosed in 2022
- Scale up short, all-oral regimens for children and pregnant populations


Pretomanid treatment courses procured from the GDF: 2021-2023



Source: Global Drug Facility (GDF)

*Data from Global Fund concept note analysis.

Children and pregnant people deserve better treatments, too



Problem

Children and pregnant women are often the last to benefit from innovation, despite being at high risk

Dosing and safety of pretomanid in children and pregnant people is still to be determined

Progress

Campaign called for research centered on neglected and excluded groups


18+ studies currently planned or underway to address 1/4/6 research gaps

Priorities

Scale up better regimens for drug-resistant TB in children and pregnant women based on endTB and BEAT-TB South Africa

Support family-centered approaches, provide resources for counselling, increase access to child-friendly formulations

Access to better treatments demands better access to diagnostics



Problem

Massive diagnostic gaps persist –ranging from 30% of people with TB not being diagnosed to 80% of children with multidrug-resistant TB not being diagnosed

Progress

All countries have plans in place to scale up access to rapid molecular diagnostics as initial TB test*

Most countries have plans to scale up access to decentralized drug-susceptibility testing*


Priorities

Increase access to rapid molecular diagnostics as initial test for all

Increase access to fluoroquinolone and isoniazid resistance testing for all

Close diagnostic gaps for children, people living with HIV and pregnant women

Achieving 1/4/6x24 : a collective call to action



Country governments

→ Increase investment

World Health Organization

→ Facilitate country dialogue on HPMZ; track and promote uptake of new regimens

Funding agencies

→ Support program quality; invest in civil society; fund research for children & pregnant people

Market-shaping actors

→ Invest in a strategy for 4HPMZ access; accelerate access to new diagnostics

Industry

→ Reduce the price of key drugs, particularly delamanid, and diagnostics

Centering the needs of people affected by TB




Peter Ngo'la Owiti

Executive Director

Wote Youth Development Projects CBO


Affected Communities Board Member

Stop TB Partnership




3HP in Malawi

1HP in Zambia



4HRZE in Kenya

4HPMZ in Azerbaijan



BPaL[M] in the Philippines

BPaL[M] in Indonesia

Learning from 1/4/6 country leaders

Facilitated by Petra Heitkamp

Edna Tembo

Coalition of Women Living with HIV Malawi

Louie Zepeda-Teng

TB People Philippines

Information systems Soliciting feedback

Community engagement

Hiring more staff Laboratory capacity

HIV & TB programs working together

Collaboration

Addressing fears & misconceptions

Transparency Capacity building

Open communication

Data sharing Investment On-the-job training

Operational research

Political commitment Stock management

Multilateral funding Updating policies

Trust

Meeting people's needs

Stakeholder consultations Domestic funding

Updating algorithms Partnerships

Quality assurance

Monitoring Financial planning Social support Stock management

Questions?

Facilitated by Asgar Ismayilov and Richa Maheshwari

Thank you



Irada Akhundova
Mubanga Angel
Mike Frick
Jennifer Furin
Farida Geteri
Mark Harrington
Petra Heitkamp
Asgar Ismayilov
Aysel Ismayilova
Immaculate Kathure
Erica Lessem
Patrick Lungu
Charisse Malbacias
Kuzani Mbendera
Lindsay McKenna
Carole Mitnick
Nkirote Mwirigi
Peter Ngo'la Owiti
Tiara Pakasi
Christophe Perrin
Nancy Rose Labarete
Tess Ryckman
Animesh Sinha
Edna Tembo
Lesya Tonkonog
Louie Zepeda-Teng

African Coalition on TB
Asia Pacific Counsel of AIDS Service Organizations
Global Coalition of TB Advocates
Global TB Community Advisory Board
Lean on Me Foundation
Médecins Sans Frontières
O'Neill Institute
Partners In Health
Results Canada
SMART4TB Consortium
Stop TB Partnership
Survivors Against TB
TB Europe Coalition
TBPPM Learning Network
TB Women Global
The Sentinel Project
Treatment Action Campaign
Treatment Action Group
We Are TB
Wote Youth Development Projects CBO
Zambia Association for Prevention of HIV and TB

1/4/6x24
A Campaign to Rally
Energy, Political Will
& Funding to End TB